SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 .

ZHENG R S , ZHANG S W , ZENG H M , et al . Cancer incidence and mortality in China, 2016 [J ] . J Natl Cancer Cent , 2022 , 2 ( 1 ): 1 - 9 .

FORASTIERE A A , METCH B , SCHULLER D E , et al . Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study [J ] . J Clin Oncol , 1992 , 10 ( 8 ): 1245 - 1251 . DOI: 10.1200/JCO.1992.10.8.1245 http://doi.org/10.1200/JCO.1992.10.8.1245

GIBSON M K , LI Y , MURPHY B , et al . Randomized phase Ⅲ evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group [J ] . J Clin Oncol , 2005 , 23 ( 15 ): 3562 - 3567 .

VERMORKEN J B , MESIA R , RIVERA F , et al . Platinum-based chemotherapy plus cetuximab in head and neck cancer [J ] . N Engl J Med , 2008 , 359 ( 11 ): 1116 - 1127 .

TAHARA M , GREIL R , RISCHIN D , et al . 659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048 [J ] . Ann Oncol , 2022 , 33 : S844 .

Nuffield Department of Primary Care Health Sciences . Oxford Centre for Evidence-Based Medicine: levels of evidence (March 2009 ) [EB/OL ] . [2023-08-10 ] . https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009 https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009 https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009

FINK A , KOSECOFF J , CHASSIN M , et al . Consensus methods: characteristics and guidelines for use [J ] . Am J Public Health , 1984 , 74 ( 9 ): 979 - 983 . DOI: 10.2105/ajph.74.9.979 http://doi.org/10.2105/ajph.74.9.979

European Society for Medical Oncology . ESMO guidelines methodology [EB/OL ] . [2023-10-04 ] . http://www.esmo.org/Guidelines/ESMO-Guidelines-Methodology http://www.esmo.org/Guidelines/ESMO-Guidelines-Methodology http://www.esmo.org/Guidelines/ESMO-Guidelines-Methodology

FERRIS R L . Immunology and immunotherapy of head and neck cancer [J ] . J Clin Oncol , 2015 , 33 ( 29 ): 3293 - 3304 . DOI: 10.1200/JCO.2015.61.1509 http://doi.org/10.1200/JCO.2015.61.1509

GONG J , CHEHRAZI-RAFFLE A , REDDI S , et al . Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations [J ] . J Immunother Cancer , 2018 , 6 ( 1 ): 8 . DOI: 10.1186/s40425-018-0316-z http://doi.org/10.1186/s40425-018-0316-z

DE RUITER E J , MULDER F J , KOOMEN B M , et al . Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC) [J ] . Mod Pathol , 2021 , 34 ( 6 ): 1125 - 1132 .

FERRIS R L , BLUMENSCHEIN G Jr , FAYETTE J , et al . Nivolumab for recurrent squamous-cell carcinoma of the head and neck [J ] . N Engl J Med , 2016 , 375 ( 19 ): 1856 - 1867 .

COHEN E E W , SOULIÈRES D , TOURNEAU C L , et al . Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study [J ] . Lancet , 2019 , 393 ( 10167 ): 156 - 167 . DOI: S0140-6736(18)31999-8 http://doi.org/S0140-6736(18)31999-8

CHOW L Q M , HADDAD R , GUPTA S , et al . Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ⅰb KEYNOTE-012 expansion cohort [J ] . J Clin Oncol , 2016 , 34 ( 32 ): 3838 - 3845 .

BAUML J , SEIWERT T Y , PFISTER D G , et al . Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase Ⅱ study [J ] . J Clin Oncol , 2017 , 35 ( 14 ): 1542 - 1549 .

EMANCIPATOR K , HUANG L K , AURORA-GARG D , et al . Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer [J ] . Mod Pathol , 2021 , 34 ( 3 ): 532 - 541 .

BURTNESS B , HARRINGTON K J , GREIL R , et al . Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J ] . Lancet , 2019 , 394 ( 10212 ): 1915 - 1928 . DOI: S0140-6736(19)32591-7 http://doi.org/S0140-6736(19)32591-7

YILMAZ E , ISMAILA N , BAUMAN J E , et al . Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers: ASCO guideline [J ] . J Clin Oncol , 2023 , 41 ( 5 ): 1132 - 1146 .

国家药品监督管理局 . phNMPA 批准PD-L1检测试剂盒(免疫组织化学法)PD-L1 IHC 22C3 pharmDx用于定性检测头颈部鳞状细胞癌(HNSCC)组织中的PD-L1蛋白,用作KEYTRUDA ® 的伴随诊断 [EB/OL ] . [2022-10-31 ] . https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9OGE4ODdiZjQ2NDU4NzE2MDAxNjQ4YzcxZDM1YzI3N2MmaXRlbUlkPWZmODA4MDgxODMwYjEwMzUwMTgzOGQ0ODcxYjUzNTQz. https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9OGE4ODdiZjQ2NDU4NzE2MDAxNjQ4YzcxZDM1YzI3N2MmaXRlbUlkPWZmODA4MDgxODMwYjEwMzUwMTgzOGQ0ODcxYjUzNTQz https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9OGE4ODdiZjQ2NDU4NzE2MDAxNjQ4YzcxZDM1YzI3N2MmaXRlbUlkPWZmODA4MDgxODMwYjEwMzUwMTgzOGQ0ODcxYjUzNTQz

National Medical Products Administration . NMPA approves PD-L1 IHC 22C3 pharmDx for qualitative detection of PD-L1 protein in head and neck squamous cell carcinoma (HNSCC) tissue as a companion diagnostic for KEYTRUDA® [EB/OL ] . [2022-10-31 ] . https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9OGE4ODdiZjQ2NDU4NzE2MDAxNjQ4YzcxZDM1YzI3N2MmaXRlbUlkPWZmODA4MDgxODMwYjEwMzUwMTgzOGQ0ODcxYjUzNTQz. https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9OGE4ODdiZjQ2NDU4NzE2MDAxNjQ4YzcxZDM1YzI3N2MmaXRlbUlkPWZmODA4MDgxODMwYjEwMzUwMTgzOGQ0ODcxYjUzNTQz https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9OGE4ODdiZjQ2NDU4NzE2MDAxNjQ4YzcxZDM1YzI3N2MmaXRlbUlkPWZmODA4MDgxODMwYjEwMzUwMTgzOGQ0ODcxYjUzNTQz

LU H Z , KUANG D , JIANG L L , et al . The PD-L1 protein expression in Chinese patients with recurrent or metastatic head and neck squamous cell carcinoma: a multi-center retrospective study [J ] . Cancer Res , 2023 , 83 ( 7_Suppl ): 5463 .

辇伟奇 , 聂勇战 , 应建明 , 等 . 肿瘤突变负荷检测及临床应用中国专家共识(2020年版) [J ] . 中国癌症防治杂志 , 2020 , 12 ( 5 ): 485 - 494 .

NIAN W Q , NIE Y Z , YING J M , et al . Chinese expert consensus on tumor mutational burden testing and clinical application [J ] . Chin J Oncol Prev Treat , 2020 , 12 ( 5 ): 485 - 494 .

SCHUMACHER T N , SCHREIBER R D . Neoantigens in cancer immunotherapy [J ] . Science , 2015 , 348 ( 6230 ): 69 - 74 . DOI: 10.1126/science.aaa4971 http://doi.org/10.1126/science.aaa4971

CHALMERS Z R , CONNELLY C F , FABRIZIO D , et al . Analysis of 100 000 human cancer genomes reveals the landscape of tumor mutational burden [J ] . Genome Med , 2017 , 9 ( 1 ): 34 .

MARABELLE A , FAKIH M , LOPEZ J , et al . Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study [J ] . Lancet Oncol , 2020 , 21 ( 10 ): 1353 - 1365 . DOI: S1470-2045(20)30445-9 http://doi.org/S1470-2045(20)30445-9

U.S. FOOD & DRUG ADMINISTRATION . FDA approves pembrolizumab for adults and children with TMB-H solid tumors [EB/OL ] . [2020-06-16 ] . https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors

HADDAD R I , SEIWERT T Y , CHOW L Q M , et al . Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma [J ] . J Immunother Cancer , 2022 , 10 ( 2 ): e003026 .

National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology (NCCN guidelines ® ) for head and neck cancer.Version 1. 2023 [EB/OL ] . [2022-12-20 ] . https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf

NGAMPHAIBOON N , TANAKA K , HONG R L , et al . Phase Ⅲ KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis [J ] . Ann Oncol , 2019 , 30 : ix97 .

默沙东中国投资有限公司 . 帕博利珠单抗注射液说明书 [Z/OL ] . [2022-11-01 ] . https://www.msdchina.com.cn/product#p1A. https://www.msdchina.com.cn/product#p1A https://www.msdchina.com.cn/product#p1A

Merck Sharp & Dohme China Investment Co., Ltd . Package insert of pembrolizumab injection [Z/OL ] . [2022-11-01 ] . https://www.msdchina.com.cn/product#p1A. https://www.msdchina.com.cn/product#p1A https://www.msdchina.com.cn/product#p1A

中国临床肿瘤学会指南工作委员会组织 . 中国临床肿瘤学会(CSCO)头颈部肿瘤诊疗指南-2023 [M ] . 北京 : 人民卫生出版社 , 2023 .

Organized by the Guidelines Working Committee of the Chinese Society of Clinical Oncology . Chinese Society of Clinical Oncology (CSCO) guidelines for diagnosis and treatment of head and neck tumors-2023 [M ] . Beijing : People's Health Publishing House , 2023 .

KEAM B , MACHIELS J P , KIM H R , et al . Pan-Asian adaptation of the EHNS-ESMO-ESTRO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck [J ] . ESMO Open , 2021 , 6 ( 6 ): 100309 .

DZIENIS M R , CUNDOM J E , FUENTES C S , et al . Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): phase Ⅵ KEYNOTE-B10 study [J ] . Ann Oncol , 2022 , 33 ( S7 ): S839 - S840 .

GUI L , HE X , YANG J , et al . Pembrolizumab plus nabpaclitaxe and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: a prospective phase Ⅱ study [J ] . Ann Oncol , 2022 , 33 ( S7 ): S855 - S856 .

BLACK C , WANG L Y , RAMAKRISHNAN K , et al . Real-world overall survival among patients receiving first-line (1L) pembrolizumab in the treatment of recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the United States [J ] . J ImmunoTher Cancer , 2022 , 10 ( S2 ): A830 - A830 .

BLACK C , WANG L Y , RAMAKRISHNAN K , et al . Real-world use of pembrolizumab combination regimens in first-line recurrent/metastatic head and neck squamous cell carcinoma [C ] // Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd , 2022 .

SEIWERT T Y , BURTNESS B , MEHRA R , et al . Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial [J ] . Lancet Oncol , 2016 , 17 ( 7 ): 956 - 965 . DOI: S1470-2045(16)30066-3 http://doi.org/S1470-2045(16)30066-3

U.S. FOOD & DRUG ADMINISTRATION . FDA approves pembrolizumab for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy [EB/OL ] . [2016-08-05 ] . https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda

SOULIERES D , HARRINGTON K J , LE TOURNEAU C , et al . Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040 [C ] . ESMO , 2022 , Abstract No. 658MO.

COHEN E E , SOULIÈRES D , LE TOURNEAU C , et al . Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040 [C ] . ASCO , 2018 , Abstract No. 6013.

U.S. FOOD & DRUG ADMINISTRATION . FDA approves nivolumab for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after a platinum-based therapy [EB/OL ] . [2016-11-10 ] . https://www.fda.gov/drugs/resources-information-approved-drugs/nivolumab-scchn https://www.fda.gov/drugs/resources-information-approved-drugs/nivolumab-scchn https://www.fda.gov/drugs/resources-information-approved-drugs/nivolumab-scchn

HADDAD R I , HARRINGTON K , TAHARA M , et al . Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: The final results of CheckMate 651 [J ] . J Clin Oncol , 2023 , 41 ( 12 ): 2166 - 2180 .

PSYRRI A , FAYETTE J , HARRINGTON K , et al . Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase Ⅲ study [J ] . Ann Oncol , 2023 , 34 ( 3 ): 262 - 274 .

SACCO A G , CHEN R F , WORDEN F P , et al . Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial [J ] . Lancet Oncol , 2021 , 22 ( 6 ): 883 - 892 . DOI: 10.1016/S1470-2045(21)00136-4 http://doi.org/10.1016/S1470-2045(21)00136-4

CHUNG C H , LI J N , STEUER C E , et al . Phase Ⅱ multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma [J ] . Clin Cancer Res , 2022 , 28 ( 11 ): 2329 - 2338 .

KAO H F , LIAO B C , HUANG Y L , et al . Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA study): a phase Ⅱ study with biomarker analysis [J ] . Clin Cancer Res , 2022 , 28 ( 8 ): 1560 - 1571 .

SABA N F , STEUER C E , EKPENYONG A , et al . Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial [J ] . Nat Med , 2023 , 29 ( 4 ): 880 - 887 . DOI: 10.1038/s41591-023-02275-x http://doi.org/10.1038/s41591-023-02275-x

TAYLOR M H , LEE C H , MAKKER V , et al . Phase ⅠB/Ⅱ trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors [J ] . J Clin Oncol , 2020 , 38 ( 11 ): 1154 - 1163 .

SIU L L , BURTNESS B , COHEN E E W , et al . Phase Ⅲ LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) [J ] . J Clin Oncol , 2020 , 38 ( 15_suppl ): TPS6589 .

HARRINGTON K J , BURTNESS B , GREIL R , et al . Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase Ⅲ KEYNOTE-048 study [J ] . J Clin Oncol , 2023 , 41 ( 4 ): 790 - 802 .

SABA N F , BLUMENSCHEIN G Jr , GUIGAY J , et al . Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by age [J ] . Oral Oncol , 2019 , 96 : 7 - 14 .

SØBY S , GOTHELF A , GYLDENKERNE N , et al . Efficacy of nivolumab as second line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a national DAHANCA cohort study [J ] . Acta Oncol , 2022 , 61 ( 8 ): 972 - 978 . DOI: 10.1080/0284186X.2022.2103387 http://doi.org/10.1080/0284186X.2022.2103387

SALEH K , AUPERIN A , MARTIN N , et al . Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck [J ] . Eur J Cancer , 2021 , 157 : 190 - 197 . DOI: 10.1016/j.ejca.2021.08.030 http://doi.org/10.1016/j.ejca.2021.08.030

CORRÊA G T , BANDEIRA G A , CAVALCANTI B G , et al . Analysis of ECOG performance status in head and neck squamous cell carcinoma patients: association with sociodemographical and clinical factors, and overall survival [J ] . Support Care Cancer , 2012 , 20 ( 11 ): 2679 - 2685 . DOI: 10.1007/s00520-012-1386-y http://doi.org/10.1007/s00520-012-1386-y

BLACK C M , WANG L Y , RAMAKRISHNAN K , et al . Real-world time on treatment analysis of pembrolizumab treated recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC) patients stratified by ECOG PS in the United States [J ] . J Clin Oncol , 2022 , 40 ( 16_suppl ): e18007 .

LANGER C , VON DER HEYDE E , HAHN D A , et al . 680P HANNA: real-world data of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), including first-line population, treated with nivolumab in Germany [J ] . Ann Oncol , 2022 , 33 : S854 .

CLINICALTRIALS GOV . Phase Ⅱ trial of pembrolizumab in recurrent or metastatic HNSCC (POPPY) [EB/OL ] . [2019-1-23 ] . https://clinicaltrials.gov/ct2/show/NCT03813836?term=POPPY & draw=5 & rank=5. https://clinicaltrials.gov/ct2/show/NCT03813836?term=POPPY&draw=5&rank=5 https://clinicaltrials.gov/ct2/show/NCT03813836?term=POPPY&draw=5&rank=5

THERASSE P , ARBUCK S G , EISENHAUER E A , et al . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [J ] . J Natl Cancer Inst , 2000 , 92 ( 3 ): 205 - 216 . DOI: 10.1093/jnci/92.3.205 http://doi.org/10.1093/jnci/92.3.205

NISHINO M . Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment [J ] . J Immunother Cancer , 2016 , 4 : 30 .

SEYMOUR L , BOGAERTS J , PERRONE A , et al . iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics [J ] . Lancet Oncol , 2017 , 18 ( 3 ): e143 - e152 . DOI: 10.1016/S1470-2045(17)30074-8 http://doi.org/10.1016/S1470-2045(17)30074-8

PARK J H , CHUN S H , LEE Y G , et al . Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12 [J ] . J Cancer Res Clin Oncol , 2020 , 146 ( 12 ): 3359 - 3369 .

ZHANG H C , FANG X F , LI D , et al . Hyperprogressive disease in patients receiving immune checkpoint inhibitors [J ] . Curr Probl Cancer , 2021 , 45 ( 3 ): 100688 .

SAÂDA-BOUZID E , DEFAUCHEUX C , KARABAJAKIAN A , et al . Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma [J ] . Ann Oncol , 2017 , 28 ( 7 ): 1605 - 1611 .

ECONOMOPOULOU P , ANASTASIOU M , PAPAXOINIS G , et al . Patterns of response to immune checkpoint inhibitors in association with genomic and clinical features in patients with head and neck squamous cell carcinoma (HNSCC) [J ] . Cancers , 2021 , 13 ( 2 ): 286 .

KARABAJAKIAN A , GARRIVIER T , CROZES C , et al . Addendum: hyperprogression and impact of tumor growth kinetics after PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma [J ] . Oncotarget , 2022 , 13 : 1305 .

KANG Y K , RECK M , NGHIEM P , et al . Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase Ⅲ, randomized, controlled trials [J ] . J Immunother Cancer , 2022 , 10 ( 4 ): e004273 .

CHAMPIAT S , DERCLE L , AMMARI S , et al . Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1 [J ] . Clin Cancer Res , 2017 , 23 ( 8 ): 1920 - 1928 . DOI: 10.1158/1078-0432.CCR-16-1741 http://doi.org/10.1158/1078-0432.CCR-16-1741

REFAE S , GAL J , BREST P , et al . Hyperprogression under immune checkpoint inhibitor: a potential role for germinal immunogenetics [J ] . Sci Rep , 2020 , 10 ( 1 ): 3565 . DOI: 10.1038/s41598-020-60437-0 http://doi.org/10.1038/s41598-020-60437-0

KATO S , GOODMAN A , WALAVALKAR V , et al . Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate [J ] . Clin Cancer Res , 2017 , 23 ( 15 ): 4242 - 4250 . DOI: 10.1158/1078-0432.CCR-16-3133 http://doi.org/10.1158/1078-0432.CCR-16-3133

BURTNESS B , HARRINGTON K , GREIL R , et al . LBA8_PRKEYNOTE-048: phase Ⅲ study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) [J ] . Ann Oncol , 2018 , 29 ( suppl_8 ): Ⅷ729 .

中国临床肿瘤学会指南工作委员会组织 . 中国临床肿瘤学会(CSCO)免疫检查点抑制剂临床应用指南-2021 [M ] . 北京 : 人民卫生出版社 , 2021 .

Organized by the Guidelines Working Committee of the Chinese Society of Clinical Oncology . Chinese Society of Clinical Oncology (CSCO) clinical application guidelines for immune checkpoint inhibitors-2021 [M ] . Beijing : People's Health Publishing House , 2021 .

National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology (NCCN guidelines) for management of immunotherapy-related toxicities.Version1.2022 [EB/OL ] . [2022-2-28 ] . https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf

WISE-DRAPER T M , GULATI S , PALACKDHARRY S , et al . Phase Ⅱ clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma [J ] . Clin Cancer Res , 2022 , 28 ( 7 ): 1345 - 1352 .

UPPALURI R , CAMPBELL K M , EGLOFF A M , et al . Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase Ⅱ trial [J ] . Clin Cancer Res , 2020 , 26 ( 19 ): 5140 - 5152 .

UPPALURI R , CHERNOCK R , MANSOUR M , et al . Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC) [J ] . J Clin Oncol , 2021 , 39 ( 15_suppl ): 6008 .

FERRIS R L , SPANOS W C , LEIDNER R , et al . Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial [J ] . J Immunother Cancer , 2021 , 9 ( 6 ): e002568 .

ZINNER R , JOHNSON J M , TULUC M , et al . Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer [J ] . J Clin Oncol , 2020 , 38 ( 15_suppl ): 6583 .

UPPALURI R , LEE N , WESTRA W , et al . KEYNOTE-689: phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma [J ] . J Clin Oncol , 2019 , 37 ( 15_suppl ): TPS6090 .